Keywords: Fabry disease; Diagnosis; Mutation; Management; Treatment; ACEI; angiotensin converting enzyme inhibitor; ARB; angiotensin receptor blocker; AV; atrioventricular; α-Gal A; α-galactosidase A; CKD; chronic kidney disease; CNS; central nervous system; CT;